Post on 03-Sep-2020
Biotech,
Pharmaceuticals
and Medical
Devices
Global Biotech, Pharmaceuticals and Medical Device Industry
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile 3
Biotech Industry - Global Overview
Technology Application Geography
►Fermentation Technology
►Tissue Engineering and Regeneration Technology
►Polymerase Chain Reaction Technology
►Nano biotechnology
►Chromatography
►DNA Sequencing Technology
►Cell based Assay
►Biopharmacy
►Bioservices
►Bioagriculture
►Bio industrial
►North America
►Europe
►Asia Pacific
►Rest of the World
Global Biotechnology market has been segmented by
R&D spend ↑ 16% to >USD 45 billion
M&A involving biotech >USD 100 billion
Innovation capital exceeds USD 41 billion
Capital raised: USD 71 billion
The biotech industry market cap: USD 863 billion in
2016
Revenues reach historic high: USD 132.7 billion
The expected global biotechnology market size: USD
414.5 billion by 2017
12
-15
14
65
18 17
28
1318 16
5
-25
0
25
50
75
100
Revenues Profitability R&D Market capitalization
Pe
rcen
tage
2013 2014 2015
250Year-over-year percentage change in financial indicators (US & Europe)
Source: Biotech Spain, EY Global Biotech Report 2017
4
Global Overview
The Value Chain – Global Biotechnology Industry
Total US and European revenues
+650%
Revenues of Top 10 US biotech firms
USD 11.8 billion USD 321 billion
US commercial leaders
717
European commercial leaders
211
Inbound Logistics Marketing & SalesOutbound LogisticsOperations
Stem cells
Serum
Bacteria
Culture
Hospitals
Pharmacy
Clinics
Trade shows
• Research
• Clinical Testing
• FDA review
• Patenting and Manufacturing
Advertisements
►Procurement and Technology development
►The industry is highly technology driven and research intensive. Certain material can be brought from only from specific agencies that provide quality products at competitive prices
Supporting Activities
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
2000 versus 2017
Source: www.statista.com
Medical Devices - Global Overview
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile 5
US continues to dominate the global medical devices market, with India and China having the highest
growth rate
The Medical Device market is forecast to grow, from $12 billion in 2013 to $17.5 billion by 2020, at a CAGR of 4.8%
Medical Devices Market: Forecast for Growth (USD in billions)
Region 2016 2017 2018 2019 2020
Americas 166.6 176.5 187.3 197.9 208.6
Asia/Pacific 68.7 72.6 77.6 82.9 88.6
Central/Eastern 14.6 15.7 17 18.1 19.1
Middle East/Africa 10 10.8 11.5 12.5 13.2
Western Europe 79.5 85.1 92.6 101.4 106.2
Total 339.5 360.8 386.1 412.8 435.8
Source: Worldwide Medical Devices Forecast to 2020, Espicom Country Reports
127
167
2013 2018
CAGR
+5.6%
6 11
2013 2018
CAGR
+13.2%
3034
2013 2018
CAGR
+2.5%
1740
2013 2018
CAGR
+18.7%
49
2013 2018
CAGR
+20.0%
64 79
2013 2018
CAGR
+4.2%
CAGR – Compound annual growth rate
Medtech market size
(US$ billion)
711
2013 2018
CAGR
+9.1%
6
Pharma Industry - Global Overview
• Develop, produce and market drugs for use as
medications
• May deal in generic or brand medications and
medical devices
• Subject to variety of laws and regulations that
govern the patenting, testing, safety, efficacy and
marketing of drugs
• Main goal is to produce drugs that prevent
infections, maintain health and cure diseases
0
500
1000
2006 2011 2016
Pharma market development 2006-16 (USD)
Emerging markets Rest of the world
The Pharma emerging markets are defined by the IMS as countries with greater than 1 USD billion absolute spending growth of more than 2012-2016 and which have GDP per capita of less than USD 25000 at purchasing power parity
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
0
500
1000
1500
2010201120122013201420152016201720182019
Global Pharma Segment Sales(USD billions)
Pharmaceutical Sales
Biotech, Pharmaceuticals and Medical Device Industry in India
India Overview
8
Drugs and Pharmaceuticals is
the among the top sectors is
India attracting highest FDI
Equity Inflows
India is a global leader in production of generic drugs
► Share in global pharmaceutical production is nearly 8%
765.4
880.5
278.6
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
2015-16 2016-17 2017-18
FDI Equity Inflows in Drugs and Pharma (in USD million)
► The Biotechnology Industry has grown from
$1.1 billion in 2005
► The bio-pharmaceutical sector accounts for the
largest share of the biotech industry with a
share of 62% of total revenues in 2015.
Indian biotech industry is expected to grow at 30.46 percent CAGR to reach USD
100 billion by 2025
Key Segments
► API Manufacturers/Traders ((Bulk Drugs)
► Formulation Manufacturers
► Contract Research and Manufacturing Services Companies
► Biotechnology Companies
Indian Pharmaceutical sector
accounts for about 2.4 per cent
of the global pharmaceutical
industry in value terms and 10
per cent in volume terms
Investment planned for medical infrastructure by 2024 is USD 200 billion
►Expected to be 3rd largest global generic Active Pharmaceutical Ingredient (API) merchant market
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
► Constitutes 70% market share, largest segment of Pharmaceuticals
► India supplies 20% of global generic medicines market exports in terms of volume
Up to June 2017
Source: DIPP 2017
Source: Pharmaceuticals- March 2017. https://www.ibef.org/download/Pharmaceutical-March-2017.pdf
Value Chain: Pharma
9
Source: EY Research
A company can operate in any one niche area or be
integrated across the value chain
Drug Discovery
NCE NDDS Reverse engineering
Clinical trials Regulatory filings
Drug development
Manufacturing
Active Ingredients
(API’s/Bulk Drugs)
Additives
(Intermediaries)
Pharmaceutical manufacturing
Formulations Filling
Manufacturing
Packaging
Marketing
Inte
gra
tio
n
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
10
Pharmaceutical Market
Indian Market
Indian companies,
4.0%
16.027.0
11.7
21.012.9
21.7
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
2015 2020F
Indian Pharma Industry
Domestic formulations Formulation exports
API exports
US$40.6 billion
US$69.7 billion
CAGR: 11.4%
Share of Indian generic exports in global generic market, 2015-16
Source: Pharmexil Annual report, 2015-16
Source: EY Research
4.35
7
1111.6
0
2
4
6
8
10
12
14
FY 13 FY 14 FY 15 FY 16 FY 17 E
Market Size of Biotech Industry (US$ billion)► Industry is growing at a CAGR of 20.33%
► Year on Year growth of 57.14 per cent in FY16
► Total industry size stood at US$ 11 billion by FY16 and
is estimated to have reached US$ 11.6 billion by FY17
► Growth driven by factors such as growing demand,
intensive R&D activities and strong government
initiatives.
► Clinical capabilities are developing fast and the country
is becoming a popular destination for clinical trials,
contract research & manufacturing activities
Biotech Industry
Source: Indian Medical Device Market Outlook, 2017
► By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and
6th largest market globally in absolute size.
► The generics market stood at US$ 26.1 billion in 2016.
► Low cost of production provides competitive edge over others.
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
11
Indian Market
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Medical Devices
► The market stood at around US$ 5.1 Billion
in 2012, is expected to grow at a rate of
around 16% during 2012-2017,
representing one of the fastest growing
medical devices markets in the world
► The sector received a total of INR 8344
Crore (approx. USD 1452 Million) between
2000 and 2016*, reflects the confidence of
global players in the Indian market
► Device market mainly dominated by
imports (almost 70%)
► Significant percentage of buyers of medical
devices are private medical institutions and
hospitals
Source: Indian Medical Device Market Outlook, 2017, Annual Report 2016-17, Ministry of Chemicals & Fertilizers
Key Segment
► Diagnostic imaging is the largest segment
in 2015
► Constitutes USD 1.18 billion in 2015 and
will grow to USD 2.47 billion in 2020
► Other and IV diagnostics comprises
electrical and electronic devices
► Orthopedics & Prosthetics and
Consumables will grow from USD 0.09
billionin 2015 to USD 1.88 billion in 2020
► Dental Products and Patient Aids will grow
from a cumulative USD 0.47 billion in 2015
to USD 1.1 billion in 2020
Market Size
► Market has grown to USD 2.02 billion in
2009 to USD 3.89 billion in 2015 at CAGR
of 15.8%.
►Constitutes nearly 1.7% of the global
device market in 2015
► Indian market contributes to 4% of Indian
healthcare market which is pegged at USD
96.7 billion
22.5 2.8
3.2 3.2 3.43.9
4.55.2
6.1
7
8.2
0
1
2
3
4
5
6
7
8
9
US
D B
illio
n
USD Billion
Growth Factors
► Growing Population
► Ageing Population
► Increasing Disease Burden of Chronic Diseases
► Increasing Health Insurance Penetration
► Growing Medical tourism
► Demand for Healthcare Infrastructure
► Emerging Healthcare Service Formats
► Quality and Accreditation of Hospitals as par with
International Standards
► India is among one of the top 2- global medical device markets and 4th largest in Asia
12
Policy Regulations
Key Milestones in Indian Pharma Sector
2010 and beyond
► The NationalPharmaceuticalPricing Policy, 2012(NPPP-2012)
► Essential drug listexpanded
► Patent-relatedrulings againstevergreening, andcompulsorylicensing
► Proposed one-taxregime (GST), to beimplemented by2016
1990-2010
► Market liberalized to promote imports and domestic production
► Patents (Amendment) Act, 2005, leading to adoption of product patents in India; attracts global pharmaceutical community
► 100% FDI allowed in pharmaceutical sector
1970-90
► Indian Patent Act, 1970
► Domestic production and participation increases with increase in production infrastructure
► India began pharmaceutical exports
Before 1970
► Low domestic
production and
market
participation;
market
dominated by
global/foreign
companies
Categories 2015 2016 2017
No.s Proposed
Investment
(INR crores)
No.s Proposed
Investment
(INR crores)
No.s Proposed
Investment
(INR crores)
Medical and Surgical
Instruments
9 200 14 224 3 442
Drugs and Pharma 79 6660 103 13952 71 6055
Source: Department of Industrial Policy and Promotion
Investment Intentions in terms of IEMs Filed, LOI/DILs Issued
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Karnataka’s Biotech, Pharmaceuticals and Medical Device Industry
Karnataka’s Unique Advantages
Knowledge Hub
for
Biotechnology
14
► Karnataka is the number 1 biotech hub in India with revenues of $ 6.5 bn in 2015 ► Karnataka Accounted for 35% of India’s Biotech Industry Revolution
► Biopharma is the biggest segment of biotech industry (~60%)
► It is home to over 60% of the country's Biotech companies► State accounts for 54% of India’s Biotech Workforce
► Biotech start-ups growing at 30% annually in the state► Karnataka contributes to around 1/3rd of the BT exports of the country► First state in the country to bring out biotech policy. Version 3 of the policy announced
recently ► Bio-Ventures Fund of INR 50 crores (USD 1 bn)► Bengaluru Bio Innovation Centre established with state-of-the-art incubation facilities► 7500+ Biotech Graduates every year
► Institute of Bio informatics and Applied Biotechnology (IBAB) offering courses for PG,
M.Sc, and PhD
► R&D group in the area of Synthetic Biology is in the process of establishment in IBAB
► Centre for Human genetics in Bengaluru Helix Park offers training in Genes analysis
particularly in area of Rare Genetics Disorders
► Ganit Lab setup in Bangalore Helix Park is the only one of its kind in the country
engaged in research and training in Bio-IT
► Institute of Agri-biotechnology setup in Dharwad
► Biotech Finishing Schools established in 12 educational institutions to provide
industry-ready graduates. Second phase of the programme- Biotechnology Skill
Enhancement Programme (BiSEP) taken up in 18 educational institutions
► Karnataka has the highest R&D expenditure in south India (3rd in the country)
► Incubation Centres for Biotech Start-ups being setup in Tier-2/3 cities
► Launched grand challenges scheme under the start-up policy for Biotech sector
► Research labs under green category
Biotech Units in Karnataka
Companies + Start-ups
380 + 194
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Karnataka’s
Pharmaceutical Industry
Karnataka’s Unique Advantages
15
► Karnataka contributes around 10% to
the country's revenue in the
pharmaceutical sector.
► The state has exclusive pharma
SEZs in Hassan and Yadgir
► Karnataka ranks 5th in pharmaceutical
exports, contributing 12% to country's
exports.
► A well developed research base with
presence of 35 Clinical Research
Organizations (CROs) and 12
Adverse Drug Reaction Reporting
Centres (ADR) assisting the industry
with clinical trials and research
► Initiatives like Venture Capital fund of
INR 50 crore (USD 1 bn) with 26%
contribution from government,
formation of Karnataka
Pharmaceutical Development Council
and the Vision Group and
promotional activities have been
introduced in the policy.
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
* Upto September 2016
Source: Economic Survey of Karnataka 2016-17
► General Dosage Forms: Tablets, capsules,
Parenteral Preparations, liquid orals, API’s
Diagnostic Kits, Dialysis Fluids, Vaccines
► Specialized categories: rDNA Products Soft
gelatin Capsules, Eye Drops, FFS, medical
Devices, cardiac Stents, Drug Eluting Stents,
Orthopedic Implants, Oral; & mechanical
Contraceptives
Karnataka’s Pharma Industry
manufactures Bulk Drugs,
Formulations and Medical devices
2,070
2,531
2,761
2,893
5,077
7,233
8,300
5,896
10,828
5,349
0 2,000 4,000 6,000 8,000 10,000 12,000
2007-08
2008-09
2009-10
2010-11
2011-12
2012-13
2013-14
2014-15
2015-16
2016-17*
Basic Chemicals, Pharmaceuticals & cosmetics Export Scenario in INR crore
(USD bn)
(82)
(167)
(91)
(128)
(111)
(78)
(45)
(42)
(39)
(32)
16
Driving Growth: Infrastructure Support
Agri Biotech Park, Dharwad
Marine Biotech Park,
Mangaluru
Animal Biotech Park, Vivarium,
Bidar
Bangalore Bio Innovation
Centre (BBC)
Nutri/ Nutraceutical and Phyto-
Pharmaceutical Park (N2P2),
Mysore
► Location - Dharwad
► R&D on gene construction. Drought tolerance, Anti phyto pathogenic genes etc.
► Collaborator – UAS
► Location – Mangaluru
► R&D on DNA sequencing, up scaling technology processing waste utilization
► Collaborator – College of Fisheries/ KVAFSU
► Location – Bidar
► R&D in disease diagnosis. Vaccine production, Embryotransfer, Bionformatics, stem cell techniques etc.
► Collaborator – KVAFSU, Bidar
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Bio Innovation
Clusters with
investment of
USD 20 mn
each
► Location – Mysuru
► R&D facility to develop various nutrition and phytopharmaceuticals
► Collaborator – CFTRI
Agri Biotech Park
Animal BT Park
Bangalore Bio Innovation Centre
Marine Biotech Park
N2P2
► Currently operational
► Common Instrumentation facility
► 25 SMEs with access to high tech instrumentationfacility
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile 17
►Exclusive Pharma Industrial areas and Pharma SEZ at Hassan and Yadgir
►Pharma Park at Mangaluru
►Pharma and MedTech Zone to be set up in Bengaluru
►Pharmaceuticals Cluster, Kolhar Indl. Area, Bidar Dist (proposed)
Driving Growth: Infrastructure Support
Infrastructure Development:
PPP based Pharma SEZs
and Technology Parks that
will include
► General infrastructure,
biotechnology finishing
schools and commercial
space
► Manufacturing units for bulk
drug formulation and
development of medical
devices
► Research and Development
Centres
► Industrial Training Centres
and PPP based vocational
training programs
► Centres of Excellence
► Innovation and Incubation
Centres for Startups
► Exclusive Pharma industrial
areas in Hassan and
Yadagir
Pharmaceutical SEZ in Yadgir
Pharma Park at Mangaluru
► Location – Bidar
► Pharmaceutical Cluster in Kolhar Industrial Area
Pharmaceutical SEZ in Hassan
GSK Pharmaceuticals is
establishing one of the world’s
largest greenfield tablets and
capsules manufacturing facility
at Vemgal in Kolar District,
Karnataka, with an estimated
investment of INR 1,000
crores (USD 15 bn)
18Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
►Ecosprin tablets
►Nizral solution
►Renerve
Leading Pharmaceutical Brands manufactured in Karnataka
►Disprin tablets
►Zental suspension
►Beplex Forte
►Corex cough syrup
►Listrine mouth wash
►Crocin tablets and syrup
►Calpol drops
►Becosules capsules
►Voveran tablets
►Benadryl syrup
Manufacturing in Karnataka
Major Players
Manufacturing in Karnataka
Major Players
19Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Companies manufacturing Medical Devices in Bengaluru, Karnataka
Companies Products Location
Skanray technologies High frequency x-ray imaging
systems, critical care device
Bengaluru
Healthium Medtech Pvt. Ltd. Suture Products and Consumables Bengaluru,
Tumakuru
BPL Medical Technologies Pvt.
Ltd.
Electrocardiographs, patient
monitors, defibrillators, central
nursing stations, stress test systems,
oxygenators, ultrasound scanners,
colposcopes, foetal monitors, foetal
Doppler and X-Rays
Bengaluru
Forus Health Pvt. Ltd. Designing and service deployment of
healthcare equipment
Bengaluru
2mpower Health Management
Services Pvt. Ltd.
Developing wearable devices Bengaluru
Embrace Innovations Inc. Medical devices like infant warmers,
etc.
Bengaluru
One Breath India Pvt. Ltd. Mechanical ventilator Bengaluru
S3V Technologies Pvt. Ltd. Cardiac stents Mysuru
Browndove Healthcare Pvt. Ltd. Catheters Bengaluru
►GE healthcare
►Medived
►Biget Labs
►Prognosys Medical,
►Opto Circuits
►Biorad Medisys
►Vascular Concepts
►Confident Dental Equipment
Other Players in to manufacturing of Medical Devices in Karnataka
Conducive Policy Environment
Karnataka
Biotech Policy
2017-2022
20
Creates specific Infrastructure –focused biotech parks in the area of
agriculture, marine biotech and animal husbandry
1Simplified administrative procedures
and special incentives
2
Increases the quality of human resources by supporting specific
educational and research institutions
3Provides general infrastructure
such as high quality roads, better power supply and airports
4
► Bangalore Bio Innovation centre with 25
fully furnished suites providing laboratory
facility to promote innovation driven R&D
start-ups
► Biotech parks-Bengaluru Helix-setup with
institutional zone, research and R&D
institutions and Bio-cluster
►Single-Window clearance mechanism
► Vision group on Biotechnology
► Incentives for Patent registration and
green initiatives
► Support for Standardization certification
► Anchor Unit Subsidy for first two
manufacturing enterprises
► Incentives for Export Oriented MSME,
Large, and Mega Project, like 100%
exemption from payment of Entry Tax
► Institutions such as IAB, IBAB, CHG and
finishing schools
► Fostering entrepreneurship and
development of new products – Med
Tech, Clean Tech, nutraceutiucals,
pharmaceuticals etc.
► Specific fiscal incentives to develop
industrial infrastructure
► Land facilitation for field trials and
experiments by agro-biotech enterprises
and scientists
Other Initiatives5
► Set up VCF with private participation-
called the KBio- VEN Fund of Rs. 50
crores
► Biotech policy 2017-22 focuses on 10
emerging areas in the Biotechnology
field
Integrated Policy Approach6
► Incentives for Biotech Start-ups under
Karnataka Startup Policy 2015-20
► Fiscal incentives and concessions
offered under the prevailing Karnataka
Industrial Policy to the biotechnology
industries and R&D centres
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Conducive Policy Environment
Integrated Policy
Approach
Karnataka Industrial
Policy 2014-19
21
Infra
stru
ctu
re
► Development of Pharmaceutical parks in potential locations of Karnataka through PPP
► Setting up of SEZs would be encouraged under the provisions in the SEZ policy
► Setting up R&D institutions to leverage the strengths of the state
► Supportive fiscal incentives and grants would be provided for promoting R&D activities
R&
D► Focus on Mega Pharmaceutical projects
► Package of Incentives & concessions offered for Investments (Industrial Policy 2014-19) like tax benefits, stamp duty exemption, green initiative benefits etc.
Ince
ntiv
es
Adm
inis
trativ
e
Measure
s
► Formation of the Karnataka Pharmaceutical Development Council and also a Vision group
► Support for promotional activities, road shows and sector specific events
Committee to promote private
pharma sector
An Inter-Ministerial coordination
Committee to review the constraints and
issues faced by the pharma industry and
facilitate resolution of these periodically
pharma firms currently have to approach
Drug Control Department for Licensing
approvals
Venture Capital Fund
Fund of INR 50 Crore with contribution of
26% from Government
Initiatives such as quick and quality
service from Drug Control Department
facilitating industries
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Annexure 7 and 8 of Karnataka Industrial Policy 2014-19 aims to develop infrastructure, foster R&D and
attract mega projects in the Pharmaceutical and Medical Device sector respectively
Enhancing Karnataka’s Skill : Biotechnology
Robust institutional ecosystem providing wide range of courses in genetics and advance courses for clinicians , R&D in other lines, supporting the growth of sector
22
Biotechnology Finishing Schools
(BTFS)
Centre for Human Genetics
Institute of Bioinformatics and
Applied Biotechnology (IBAB)
► 12 schools have been established for Post Graduate
Diploma (8 BT Domains)
► Capacity for 300 students per year
► Conduct courses/workshops for scientists & clinicians
► Address lacunae in research and education including
rare genetic disorders
► Centre of Excellence functioning since 2001 offering
courses for PG (300 students), MSc (80 students),
PhD (4-10 pursuing) and modular courses
Leading Institutions in Karnataka
► Indian Institute of Science, Bengaluru
► National Centre for Biological
Sciences, Bengaluru
► Jawaharlal Nehru Centre for Advanced
Scientific Research, Bengaluru
► National Institute of Mental Health and
Neurosciences, Bengaluru
► Indian Institute of Horticulture
Research, Bengaluru
► Karnataka Veterinary, Animal &
Fisheries Science, University, Bidar
► University of Agriculture Sciences-
Bengaluru, Dharwad, Raichur,
Shivamogga
► Institute for Agriculture Biotechnology,
Dharwad
► Central Food Technological Research
Institute, Mysuru
Resulting in
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
An average of 65% of job placements of BTFSstudents thus far across 5 years
61 82
120
► Pharmacy Colleges providing B.Pharmdegree to 1270 students in the year 2016-17
► Post GraduationEnrolment capacity for M.D. (Pharmacology) in 2016-17
► Pharmacists trained under Integrated Disease Surveillance Project (IDSP) in 2015-16
50
► Research base with presence of CROs assisting industry with clinical research and trials
23
Enhancing Karnataka’s Skill: Pharma
Large number of
medical education
institutions creating
an ecosystem for
collaboration on
product
development and
trials
Type of institutions Number Enrolments
(Government)
Medical colleges (MBBS) 42 2,668
Ayurvedic Colleges 63 936
Homeopathic Colleges (BHMS) 11 253
Unani Colleges 04 81
Naturopathy & Yogic Services (BNYS) 04 79
Dental Colleges (BDS) 39 1,216
Pharmacy Colleges (B.Pharm) 61 1270
Farm Science 39 2,645
Source: Karnataka Examinations Authority 2017: http://kea.kar.nic.in/
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Source: Economic Survey of Karnataka 2016-17
AgriProducts
Pharma
Environment
Energy
Medical Devices
24Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Area of Investments
► Biotech Crops (Pulses, Cereals,
Plantation crops)
► Aerobic Rice (Water saving)
► Sugarcane Alternative products
► Bioremediation
► Conversion of waste to useful
products
► Biofuels
► Marine Biology
► Vaccine Technologies
► Drug discovery
► Synthetic Biology
► Generic Drug
Manufacturing
1,914
1,550
0
500
1,000
1,500
2,000
2,500
Investment (in INR Cr) Employment (in Nos.)
SHLCC Approved Projects from 2013-14 to 2016-17
2,201.21
6,369
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
Investment (in INR Cr) Employment (in Nos.)
SLSWCC Approved Projects from 2013-14 to 2016-17
► Surgical, Cardiac Stents,
Catheters, Renal Tubes,
Dental, orthopaedic,
ophthalmologic, laboratory
instruments, etc.
Investment Opportunities
25Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
► An annual incentive up to 20% of expenditure
towards clinical trials for bio availability and
bio-equivalence subject to a maximum of INR
100 lakh per clinical trial under Industrial Policy
2014-19
► Nutraceutical and Phyto pharmaceutical
Incubation Centre and Common
Instrumentation Facility, stage –II is under
development to provide space for more
incubates
► Special Incentives to Medical Devices Sector
to encourage Establishment of Medical
Devices Park
► Showcasing Karnataka Medical Devices
Sector: A grant up to 50% of the cost subject
to a maximum of INR 300 lakh to organize the
biennial event of trade show and conferences
► Initiate establishment of Incubation Centre
cum Common Instrumentation Facility to
promote Marine/Aqua Biotech
► Expert Group on Agriculture Biotechnology
(EGAB) constituted as a sub group of VGBT
(Vision Group on Biotechnology)
► Sanctioned INR 8.5 crore spread over 3
years to University of Horticulture Sciences,
Bagalkote, to carry out R&D on Tomato,
Banana, Pomegranate and Garcinia; to
develop resistance to diseases and
establishment of germplasm / gene banks
► A grant of INR 6.5 crore sanctioned has been
completely released to UAS Dharwad
► Karnataka Biotechnology & Information
Technology Services (KBITS) established in
2000 facilitates Biotechnology Industries in
the state and administers incentives and
concessions to Biotechnology companies
► Karnataka Drugs and Pharmaceuticals
Manufacturers’ Association insists on 100%
implementation of Pharma Policy and Parks
► Karnataka Pharmaceutical Development Cell
(KPDC) to serve as a dedicated single point
contact for pharmaceutical sector
Investment Facilitation
Contact Details
Additional Chief Secretary to
Govt. of Karnataka, Health &
Family Welfare ServicesAdditional Chief Secretary to Govt. of
Karnataka, Health & Family Welfare
Services, #105,
I Floor, Vikas Soudha,
Bangalore - 560 001
Phone: 91-80-2225 5324
Fax: 91-80-2235 3916
Email: prs-hfw@karnataka.gov.in
Principal Secretary to
Government,
Dept. of Information
Technology, Biotechnology
and Science & technologyVI Floor, 5th Stage, M.S.Building,
Ambedkar Veedhi,
Bengaluru - 560 001
Tel: 91-80-2228 0562
Fax: 91-80-2228 8340
Email: itsec@bangaloreitbt.in
26
Commissioner for Industrial
Development and
Director of Industries & Commerce2nd Floor, Khanija Bhavan, No.49,Race Course
Road, Bangaluru 560 001
Ph : 91-80-2238 6796,
Fax : 91-80-2238 9909
Email: commissioner@karnatakaindustry.gov.in
Vendor Development and Investor Summit 2017- Biotech, Pharmaceuticals and Medical Devices - Sector Profile
Managing Director
Karnataka Udyog Mitra3rd Floor, East Wing, Khanija Bhavan,
Race Course Road,
Bengaluru – 560 001
Phone : 91-80-2228 2392
Email: md@kumbangalore.com
Chief Executive Officer
Invest Karnataka Forum3rd Floor, East Wing, Khanija Bhavan,
Race Course Road,
Bengaluru – 560 001
Phone : 91-80-2228 2392
Email: ceo@investkarnataka.co.in